Athira Pharma, Inc. (NASDAQ: ATHA), a clinical stage biopharmaceutical company, has announced the results of its Phase 1 clinical trial for ATH-1105, a novel orally available drug candidate. The results were presented at the ALS Nexus 2025 conference in Dallas, Texas. ATH-1105 is designed to modulate the neurotrophic HGF system, targeting neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS). The trial demonstrated a favorable safety and tolerability profile, along with dose-proportional pharmacokinetics and CNS penetration. These findings support the continued development of ATH-1105, which has previously shown beneficial effects in preclinical models of ALS.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Athira Pharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9512008-en) on August 14, 2025, and is solely responsible for the information contained therein.